{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:18:17Z","timestamp":1780917497688,"version":"3.54.1"},"reference-count":57,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["openrespiratorymedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORMJ"],"published-print":{"date-parts":[[2015,3,31]]},"abstract":"<jats:p>There is currently less experience with inhaled tobramycin in non-cystic fibrosis bronchiectasis than in cystic fibrosis (CF). Intravenous formulation and solution for inhalation (TSI) have been studied in non-CF bronchiectasis patients with chronic P. aeruginosa bronchial infection. An improvement in clinical parameters and a reduction in bacterial density have been shown with both inhaled solutions in these patients. However, further trials are needed to determine the most effective dose and administration protocol in these patients. Based on the current evidence, recommendations cannot be made regarding the use of TSI to treat exacerbations. Although no systemic toxicity has been reported in studies specifically investigating this treatment, patients with known kidney disease or ear disorders should be treated with caution. Adverse respiratory effects are reported to be more common in non-CF patients than in CF patients, who tend to be non-smokers and younger. Research is being conducted into the possibility of combining tobramycin with other antibiotics to increase its antibacterial activity. In this review we will present and discuss the published evidence regarding the use of inhaled tobramycin in non\u2013CF bronchiectasis.<\/jats:p>","DOI":"10.2174\/1874306401509010030","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T05:36:47Z","timestamp":1429076207000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis"],"prefix":"10.2174","volume":"9","author":[{"given":"Montserrat","family":"Vendrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier de","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","first-page":"53","volume":"21","author":"Olsen AM","year":"1946","unstructured":"Olsen AM. \n                    Streptomycin aerosol in the treatment of chronic bronchiectasis; preliminary report. \n                    Proc Staff Meet Mayo Clin  \n                    1946; \n                    21\n                    : 53.","journal-title":"Proc Staff Meet Mayo Clin."},{"key":"refR2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(83)92428-5","volume":"1","author":"Wall MA","year":"1983","unstructured":"Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. \n                    Inhaled antibiotics in cystic fibrosis. \n                    Lancet  \n                    1983; \n                    1\n                    : 1325.","journal-title":"Lancet."},{"key":"refR3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0007-0971(87)90184-7","volume":"81","author":"Carswell F","year":"1987","unstructured":"Carswell F, Ward C, Cook DA, Speller DCE. \n                    A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. \n                    Br J Dis Chest  \n                    1987; \n                    81\n                    : 356-60.","journal-title":"Br J Dis Chest."},{"key":"refR4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","volume":"7","author":"MacLusky IB","year":"1989","unstructured":"MacLusky IB, Gold R, Corey M, Levison H. \n                    Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. \n                    Pediatr Pulmonol  \n                    1989; \n                    7\n                    : 42-8.","journal-title":"Pediatr Pulmonol."},{"key":"refR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"Ramsey BW","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM , et al. \n                    Intermittent administration of inhaled tobramycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobramycin Study Group. \n                    N Engl J Med  \n                    1999; \n                    340\n                    : 23-30.","journal-title":"N Engl J Med."},{"key":"refR6","volume":"3","author":"Ryan G","year":"2000","unstructured":"Ryan G, Mukhopadhyay S, Singh M. \n                    Nebulised antipseudomonal antibiotics for cystic fibrosis (Cochrane Review). \n                    In The Cochrane Library Oxford Update Software  \n                    2000; \n                    3","journal-title":"In The Cochrane Library Oxford Update Software"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/00003495-200363220-00015","volume":"63","author":"Cheer SM","year":"2003","unstructured":"Cheer SM, Waugh J, Noble S. \n                    Inhaled tobramycin (TOBI).A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.  \n                    Drugs  \n                    2003; \n                    63\n                    : 2501-0.","journal-title":"Drugs."},{"key":"refR8","first-page":"755","volume":"2","author":"Singh MP","year":"2001","unstructured":"Singh MP. \n                    Tobramycin (Cystic Fibrosis Foundation\/PathoGenesis). \n                    Curr Opin Investig Drugs  \n                    2001; \n                    2\n                    : 755-65.","journal-title":"Curr Opin Investig Drugs."},{"key":"refR9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.pupt.2009.06.001","volume":"22","author":"Chuchalin A","year":"2009","unstructured":"Chuchalin A, Amelina E, Bianco F. \n                    Tobramycin for inhalation in cystic fibrosis Beyond respiratory improvements. \n                    Pulm Pharmacol Ther  \n                    2009; \n                    22\n                    : 526-32.","journal-title":"Pulm Pharmacol Ther."},{"key":"refR10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1378\/chest.122.3.930","volume":"122","author":"Alothman GA","year":"2002","unstructured":"Alothman GA, Alsaadi MM, Ho BL , et al. \n                    Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. \n                    Chest  \n                    2002; \n                    122\n                    : 930-4.","journal-title":"Chest."},{"key":"refR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/089426800418677","volume":"13","author":"Standaert TA","year":"2000","unstructured":"Standaert TA, Vandevanter D, Ramsey BW , et al. \n                    The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. \n                    J Aerosol Med  \n                    2000; \n                    13\n                    : 147-53.","journal-title":"J Aerosol Med."},{"key":"refR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2010.08.019","volume":"10","author":"Lenney W","year":"2011","unstructured":"Lenney W, Edenborough F, Kho P, Kovarik JM. \n                    Lung deposition of inhaled tobramycin with eFlow rapid\/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. \n                    J Cyst Fibros  \n                    2011; \n                    10\n                    : 9-14.","journal-title":"J Cyst Fibros."},{"key":"refR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00148581-200709001-00002","volume":"9","author":"Poli G","year":"2007","unstructured":"Poli G, Acerbi D, Pennini R , et al. \n                    Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. \n                    Paediatr Drugs  \n                    2007; \n                    9\n                    (Suppl 1\n            )\n                    : 3-9.","journal-title":"Paediatr Drugs."},{"key":"refR14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ppul.22989","volume":"49","author":"Mazurek H","year":"2014","unstructured":"Mazurek H, Chiron R, Kucerova T , et al. \n                    Long-term efficacy and safety of aerosolized tobramycin 300\u03bamg\/4\u03baml in cystic fibrosis. \n                    Pediatr Pulmonol  \n                    2014; \n                    49\n                    : 1076-89.","journal-title":"Pediatr Pulmonol."},{"key":"refR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","volume":"10","author":"Konstan MW","year":"2011","unstructured":"Konstan MW, Flume PA, Kappler M , et al. \n                    Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients The EAGER trial. \n                    J Cyst Fibros  \n                    2011; \n                    10\n                    : 54-61.","journal-title":"J Cyst Fibros."},{"key":"refR16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcf.2014.04.006","volume":"13","author":"Sands D","year":"2014","unstructured":"Sands D, Sapiejka E, G\u03baszczyk G, Mazurek \n                            . \n                    for the T100 Study Group.Comparison of two tobramycin nebuliser solutions Pharmacokietic efficacy and safety profiles of T100 and TNS. \n                     J Cyst Fibros  \n                     2014; \n                     13\n                    : 653-0.","journal-title":"J Cyst Fibros."},{"key":"refR17","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1128\/AAC.49.8.3382-3386.2005","volume":"49","author":"Maci\u00e1 MD","year":"2005","unstructured":"Maci\u00e1 MD, Blanquer D, Togores B, Sauleda J, P\u00e9rez JL, Oliver A. \n                    Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. \n                    Antimicrob Agents Chemother  \n                    2005; \n                    49\n                    : 3382-6.","journal-title":"Antimicrob Agents Chemother."},{"key":"refR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","volume":"5","author":"Chalmers JD","year":"2013","unstructured":"Chalmers JD, Hill AT. \n                    Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. \n                    Mol Immunol  \n                    2013; \n                    5\n                    : 27-34.","journal-title":"Mol Immunol."},{"key":"refR19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1469-0691.2005.01217.x","volume":"11","author":"Cant\u00f3n R","year":"2005","unstructured":"Cant\u00f3n R, Cobos N, de Gracia J , et al. \n                    Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. \n                    Clin Microbiol Infect  \n                    2005; \n                    11\n                    : 690-703.","journal-title":"Clin Microbiol Infect."},{"key":"refR20","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1183\/09031936.05.00055705","volume":"26","author":"Woodhead M","year":"2005","unstructured":"Woodhead M, Blasi F, Ewig S , et al. \n                    Guidelines for the management of adult lower respiratory tract infections. \n                    Eur Respir J  \n                    2005; \n                    26\n                    : 1138-80.","journal-title":"Eur Respir J."},{"key":"refR21","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.1378\/chest.129.1_suppl.122S","volume":"129","author":"Rosen MJ","year":"2006","unstructured":"Rosen MJ. \n                    Chronic cough due to bronchiectasis ACCP evidence-based clinical practice guidelines. \n                    Chest  \n                    2006; \n                    129\n                    (Suppl 1\n    )\n                    : 122S-31S.","journal-title":"Chest."},{"key":"refR22","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"7","author":"Woodhead M","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S , et al. \n                    Guidelines for the management of adult lower respiratory tract infections--full version. \n                    Clin Microbiol Infect  \n                    2011; \n                    7 \n                    (Suppl 6\n    )\n                    : E1-59.","journal-title":"Clin Microbiol Infect."},{"key":"refR23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.30.6.562","volume":"30","author":"Le J","year":"2010","unstructured":"Le J, Ashley ED, Neuhauser MM , et al. \n                    Consensus summary of aerosolized antimicrobial agents application of guideline criteria.Insights from the Society of Infectious Diseases Pharmacists. \n                     Pharmacotherapy  \n                    2010; \n                    30\n                    : 562-84.","journal-title":"Pharmacotherapy."},{"key":"refR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","volume":"186","author":"Chalmers JD","year":"2012","unstructured":"Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan Jr, Hill AT. \n                    Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. \n                    Am J Respir Crit Care Med  \n                    2012; \n                    186\n                    : 657-.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR25","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","volume":"10","author":"Wilson CB","year":"1997","unstructured":"Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. \n                    Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. \n                    Eur Respir J  \n                    1997; \n                    10\n                    : 1754-60.","journal-title":"Eur Respir J."},{"key":"refR26","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","volume":"43","author":"Mart\u00ednez-Garc\u00eda M","year":"2014","unstructured":"Mart\u00ednez-Garc\u00eda M , de Gracia J, Vendrell Relat M , et al. \n                    Multidimensional approach to non-cystic fibrosis bronchiectasis the FACED score. \n                    Eur Respir J  \n                    2014; \n                    43\n                    : 1357-67.","journal-title":"Eur Respir J."},{"key":"refR27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"Chalmers JD","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S , et al. \n                    The bronchiectasis severity index.An international derivation and validation study. \n                     Am J Respir Crit Care Med  \n                    2014; \n                    189\n                    : 576-85.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","volume":"132","author":"Martinez-Garcia MA","year":"2007","unstructured":"Martinez-Garcia MA, Soler-Catalu\u00f1a JJ, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soriano J. \n                    Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. \n                    Chest  \n                    2007; \n                    132\n                    : 1565-72.","journal-title":"Chest."},{"key":"refR29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1183\/09031936.06.00074605","volume":"28","author":"Davies G","year":"2006","unstructured":"Davies G, Wells AU, Doffman S , et al. \n                    The effect of pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. \n                    Eur Respir J  \n                    2006; \n                    28\n                    : 974-79.","journal-title":"Eur Respir J."},{"key":"refR30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MCP.0b013e328312ed8c","volume":"14","author":"Bilton D","year":"2008","unstructured":"Bilton D. \n                    Update on non-cystic fibrosis bronchiectasis. \n                    Curr Opin Pulm Med  \n                    2008; \n                    14\n                    : 595-9.","journal-title":"Curr Opin Pulm Med."},{"key":"refR31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1157\/13128330","volume":"44","author":"Vendrell M","year":"2008","unstructured":"Vendrell M, de Gracia J, Olveira C , et al. \n                    Diagnosis and treatment of bronchiectasis.Spanish Society of Pneumology and Thoracic Surgery. \n                     Arch Bronconeumol  \n                    2008; \n                    44\n                    : 629-40.","journal-title":"Arch Bronconeumol."},{"key":"refR32","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"Pasteur MC","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT. \n                    British Thoracic Society Bronchiectasis non-CF Guideline Group British Thoracic Society guideline for non-CF bronchiectasis. \n                    Thorax  \n                    2010; \n                    65\n                    (Suppl 1\n    )\n                    : i1-58.","journal-title":"Thorax."},{"key":"refR33","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","volume":"93","author":"Orriols R","year":"1999","unstructured":"Orriols R, Roig J, Ferrer J , et al. \n                    Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. \n                    Respir Med  \n                    1999; \n                    93\n                    : 476-80.","journal-title":"Respir Med."},{"key":"refR34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","volume":"39","author":"Drobnic ME","year":"2005","unstructured":"Drobnic ME, Su\u00f1\u00e9 P, Montoro JB, Ferrer A, Orriols R. \n                    Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. \n                    Ann Pharmacother  \n                    2005; \n                    39\n                    : 39-44.","journal-title":"Ann Pharmacother."},{"key":"refR35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","volume":"162","author":"Barker AF","year":"2000","unstructured":"Barker AF, Couch L, Fiel SB , et al. \n                    Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. \n                    Am J Respir Crit Care Med  \n                    2000; \n                    162\n                    : 481-85.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR36","first-page":"1420","volume":"127","author":"Scheinberg P","year":"2005","unstructured":"Scheinberg P, Shore E. \n                    A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. \n                    Chest  \n                    2005; \n                    127\n                    : 1420-6.","journal-title":"Chest."},{"key":"refR37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","volume":"189","author":"Haworth CS","year":"2014","unstructured":"Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. \n                    Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. \n                    Am J Respir Crit Care Med  \n                    2014; \n                    189\n                    : 975-82.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","volume":"183","author":"Murray MP","year":"2011","unstructured":"Murray MP, Govan Jr, Doherty CJ , et al. \n                    A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. \n                    Am J Respir Crit Care Med  \n                    2011; \n                    183\n                    : 491-9.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR39","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","volume":"41","author":"Wilson R","year":"2013","unstructured":"Wilson R, Welte T, Polverino E , et al. \n                    Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis a phase II randomised study. \n                    Eur Respir J  \n                    2013; \n                    41\n                    : 1107-5.","journal-title":"Eur Respir J."},{"key":"refR40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","volume":"68","author":"Serisier DJ","year":"2013","unstructured":"Serisier DJ, Bilton D, De Soyza A , et al. \n                    Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. \n                    Thorax  \n                    2013; \n                    68\n                    : 812-7.","journal-title":"Thorax."},{"key":"refR41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"Wong C","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N , et al. \n                    Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. \n                    Lancet  \n                    2012; \n                    380\n                    : 660-7.","journal-title":"Lancet."},{"key":"refR42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/thx.2002.003236","volume":"60","author":"Tsang KW","year":"2005","unstructured":"Tsang KW, Tan KC, Ho PL , et al. \n                    Inhaled fluticasone in bronchiectasis a 12 month study. \n                    Thorax  \n                    2005; \n                    60\n                    : 239-43.","journal-title":"Thorax."},{"key":"refR43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","volume":"107","author":"Stockley R","year":"2013","unstructured":"Stockley R, De Soyza A, Gunawardena K , et al. \n                    Phase II study of a neutrophil elastase inhibitor (AZD9668):in patients with bronchiectasis. \n                    Respir Med  \n                    2013; \n                    107\n                    : 524-33.","journal-title":"Respir Med."},{"key":"refR44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","volume":"20","author":"Hodson ME","year":"2002","unstructured":"Hodson ME, Gallagher CG, Govan Jr. \n                    A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. \n                    Eur Respir J  \n                    2002; \n                    20\n                    : 658-4.","journal-title":"Eur Respir J."},{"key":"refR45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","volume":"2","author":"Assael BM","year":"2013","unstructured":"Assael BM, Pressler T, Bilton D , et al. \n                    Inhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis A comparative efficacy trial. \n                    J Cyst Fibros  \n                    2013; \n                    2\n                    : 130-40.","journal-title":"J Cyst Fibros."},{"key":"refR46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","volume":"64","author":"MacLeod DL","year":"2009","unstructured":"MacLeod DL, Barker LM, Sutherland JL , et al. \n                    Antibacterial activities of a fosfomycin\/tobramycin combination a novel inhaled antibiotic for bronchiectasis. \n                    J Antimicrob Chemother  \n                    2009; \n                    64\n                    : 829-36.","journal-title":"J Antimicrob Chemother."},{"key":"refR47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","volume":"185","author":"Trapnell BC","year":"2012","unstructured":"Trapnell BC, McColley SA, Kissner DG , et al. \n                    Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. \n                    Am J Respir Crit Care Med  \n                    2012; \n                    185\n                    : 171-8.","journal-title":"Am J Respir Crit Care Med."},{"key":"refR48","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1128\/AAC.00372-10","volume":"54","author":"Tr\u00e9-Hardy M","year":"2010","unstructured":"Tr\u00e9-Hardy M, Nagant C, El Manssouri N , et al. \n                    Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. \n                    Antimicrob Agents Chemother  \n                    2010; \n                    54\n                    : 4409-15.","journal-title":"Antimicrob Agents Chemother."},{"key":"refR49","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/656788","volume":"202","author":"Herrmann G","year":"2010","unstructured":"Herrmann G, Yang L, Wu H , et al. \n                    Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. \n                    J Infect Dis  \n                    2010; \n                    202\n                    : 1585-92.","journal-title":"J Infect Dis."},{"key":"refR50","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","volume":"130","author":"Bilton D","year":"2006","unstructured":"Bilton D, Henig N, Morrisey B, Gotfried M. \n                    Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. \n                    Chest  \n                    2006; \n                    130\n                    : 1503-0.","journal-title":"Chest."},{"key":"refR51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006454-198305000-00007","volume":"2","author":"Stephens D","year":"1983","unstructured":"Stephens D, Garey N, Isles A, Levison H, Gold R. \n                    Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. \n                    Pediatr Infect Dis  \n                    1983; \n                    2\n                    : 209-11.","journal-title":"Pediatr Infect Dis."},{"key":"refR52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jamp.2013.1055","volume":"27","author":"Al-Aloul M","year":"2014","unstructured":"Al-Aloul M, Nazareth D, Walshaw M. \n                    Nebulized Tobramycin in the Treatment of Adult CF Pulmonary Exacerbations. \n                    J Aerosol Med Pulm Drug Deliv  \n                    2014; \n                    27\n                    : 299-305.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"refR53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","volume":"3","author":"D\u00f6ring G","year":"2004","unstructured":"D\u00f6ring G, Hoiby N. \n                    Consensus Study Group.Early intervention and prevention of lung disease in cystic fibrosis a European consensus. \n                     J Cyst Fibros  \n                    2004; \n                    3\n                    : 67-91.","journal-title":"J Cyst Fibros."},{"key":"refR54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ppul.10185","volume":"34","author":"Hoffmann IM","year":"2002","unstructured":"Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. \n                    Acute renal failure in cystic fibrosis association with inhaled tobramycin therapy. \n                    Pediatr Pulmonol  \n                    2002; \n                    34\n                    : 375-7.","journal-title":"Pediatr Pulmonol."},{"key":"refR55","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.healun.2004.05.008","volume":"24","author":"Ahya VN","year":"2005","unstructured":"Ahya VN, Doyle AM, Mendez JD , et al. \n                    Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. \n                    J Heart Lung Transplant  \n                    2005; \n                    24\n                    : 932-5.","journal-title":"J Heart Lung Transplant."},{"key":"refR56","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5414\/CNP66464","volume":"66","author":"Izquierdo MJ","year":"2006","unstructured":"Izquierdo MJ, Gomez-Alamillo C, Ortiz F , et al. \n                    Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. \n                    Clin Nephrol  \n                    2006; \n                    66\n                    : 464-7.","journal-title":"Clin Nephrol."},{"key":"refR57","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1128\/JCM.43.9.4480-4485.2005","volume":"43","author":"Morosini MI","year":"2005","unstructured":"Morosini MI, Garc\u00eda-Castillo M, Loza E, P\u00e9rez-V\u00e1zquez M, Baquero F, Cant\u00f3n R. \n                    Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients use of high-range Etest strips. \n                    J Clin Microbiol  \n                    2005; \n                    43\n                    : 4480-5.","journal-title":"J Clin Microbiol."}],"container-title":["The Open Respiratory Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V9\/TORMJ-9-30\/TORMJ-9-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V9\/TORMJ-9-30\/TORMJ-9-30.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V9\/TORMJ-9-30\/TORMJ-9-30.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T01:39:15Z","timestamp":1561081155000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrespiratorymedicinejournal.com\/VOLUME\/9\/PAGE\/30\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,31]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3,31]]}},"alternative-id":["TORMJ-9-30"],"URL":"https:\/\/doi.org\/10.2174\/1874306401509010030","relation":{},"ISSN":["1874-3064"],"issn-type":[{"value":"1874-3064","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2014-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-3-3","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-3-3","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-3-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}